A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
| Status: | Archived |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2011 |
| End Date: | January 2012 |
A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease
This is a two-part study. The purpose of the pilot study (Part 1) is to optimize the
acquisition, handling and shipping procedure for skin biopsies obtained from participants
with plaque psoriasis. No treatment will be administered. Part 2 will include 2 cohorts. In
Cohort 1, the effects of 16 weeks of treatment with either ustekinumab or etanercept on
biomarkers in lesional skin in participants with moderate to severe psoriasis will be
evaluated. In Cohort 2, biomarkers of lesional skin from participants with moderate to
severe psoriasis who are not treated with biologic therapy will be evaluated over 16 weeks.
We found this trial at
1
site
Click here to add this to my saved trials
